Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Blogs » ED Push » Study Confirms Value of Idarucizumab in Reversing Blood Thinner Dabigatran

    ED Push
    ED Push RSS FeedRSS

    edpush-webheader-rm

    Free Monthly News from the Award Winning Publisher of:

    • Emergency Medicine Reports
    • Trauma Reports
    • Critical Care Alert
    • ED Management
    • ED Legal Letter
    • Pediatric Emergency Medicine Reports
    • EM Reports' Study Guide 2018
    • STROKE: The Cutting Edge: 2017
    • Pediatric Trauma 2018
    • STEMI Watch 2018
     

     

    Study Confirms Value of Idarucizumab in Reversing Blood Thinner Dabigatran

    August 2, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    By Brenda Mooney

    A new study confirms the effectiveness and safety of an agent that reverses the action of the blood thinner dabigatran.

    Results of the RE-VERSE AD clinical trial were published recently in The New England Journal of Medicine.

    “In emergency situations, idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran,” an international team of researchers conclude from the industry-funded study.

    Background information in the article notes that about 28 million prescriptions for blood thinners are filled by pharmacists annually for atrial fibrillation, deep vein thrombosis, and other conditions. In rare cases, those patients end up at the emergency department because of accidental bleeding and hemorrhage related to their medications.

    “Prior to idarucizumab, there was no rapid, reliable, and effective method for reversing dabigatran and other orally administered blood thinners, which otherwise may take at least 12 to 24 hours to clear from the body,” explains lead author Charles Pollack, MD, professor of Emergency Medicine at Sidney Kimmel Medical College of Thomas Jefferson University. “Physicians will now have a potentially life-saving option for treating patients at risk of uncontrolled bleeding or in need of emergency surgery.”

    The study, which included 503 patients taking dabigatran with an urgent medical need to reverse the blood thinner, was conducted in 39 countries between 2014 and 2016. Participants were divided into two groups — one including patients with uncontrolled bleeding or hemorrhage, and the other with patients requiring emergency surgery that could not be safely performed while the patient was affected by anticoagulants.

    Patients were given one dose of five grams of idarucizumab, with only nine requiring a second dose. Blood was evaluated for clotting ability before the reversal agent was administered, and then at six points afterward.

    Results indicated that idarucizumab returned patients to normal clotting function within minutes of administration; the first tested time point was between 10-30 minutes after the dosage was received.

    In patients with uncontrolled bleeding, meanwhile, idarucizumab stemmed the bleeding within a median of 2.5 hours. In fact, patients requiring surgery were able to begin the procedure an average of 1.6 hours after dosing.

    The reversal agent from Boehringer Ingelheim Pharmaceuticals is made from an antibody segment that functions by binding tightly and specifically to dabigatran and preventing the anticoagulant effects. The study emphasized that idarucizumab is not an antidote to other anticoagulants.

    In 2015, interim results of RE-VERSE AD were published based on analysis of results from 90 patients. Using that data, both the U.S. Food and Drug Administration and the European Medicines Agency granted approval for use of the drug in emergency settings.

    Now, the new study reaffirms the interim findings. “For the first time we have the ability to turn off oral anticoagulation like a light switch,” Pollack says. “In the past, we haven’t had the ability to do that.”

     

    newsletter-sponsors-relias_sr

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    ED Push

    View PDF
    ED Push - August 2017 First Issue
    August 1, 2017

    Table Of Contents

    EHR Reminders Nudge ED Physicians to Right-Size Imaging Usage

    Acute Kidney Injury Patients Remain at Risk After ED Discharge

    Study Confirms Value of Idarucizumab in Reversing Blood Thinner Dabigatran

    Many Anaphylactic Children Don’t Receive Epinephrine Before ED Visit

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing